PML-mediated nuclear loosening permits immunomodulation of mesenchymal stem/stromal cells under inflammatory conditions

Abstract

Nuclear configuration plays a critical role in the compartmentalization of euchromatin and heterochromatin and the epigenetic regulation of gene expression. Under stimulation by inflammatory cytokines IFN-γ and TNF-α, human mesenchymal stromal cells (hMSCs) acquire a potent immunomodulatory function enabled by drastic induction of various effector genes, with some upregulated several magnitudes. However, whether the transcriptional upregulation of the immunomodulatory genes in hMSCs exposed to inflammatory cytokines is associated with genome-wide nuclear reconfiguration has not been explored. Here, we demonstrate that hMSCs undergo remarkable nuclear reconfiguration characterized by an enlargement of the nucleus, downregulation of LMNB1 and LMNA/C, decondensation of heterochromatin, and derepression of repetitive DNA. Interestingly, promyelocytic leukaemia-nuclear bodies (PML-NBs) were found to mediate the nuclear reconfiguration of hMSCs triggered by the inflammatory cytokines. Significantly, when PML was depleted, the immunomodulatory function of hMSCs conferred by cytokines was compromised, as reflected by the attenuated expression of effector molecules in hMSCs and their failure to block infiltration of immune cells to lipopolysaccharide (LPS)-induced acute lung injury. Our results indicate that the immunomodulatory function of hMSCs conferred by inflammatory cytokines requires PML-mediated chromatin loosening.

References

[1] Gao L, Wu K, Liu Z, et al. Chromatin accessibility landscape in human early embryos and its association with evolution. Cell. 2018;173(1):248-259. e15.

[2] Klemm SL, Shipony Z, Greenleaf WJ. Chromatin accessibility and the regulatory epigenome. Nat Rev Genet. 2019;20(4):207-220.

[3] Gorkin DU, Barozzi I, Zhao Y, et al. An atlas of dynamic chromatin landscapes in mouse fetal development. Nature. 2020;583(7818):744-751.

[4] Misteli T. The self-organizing genome: principles of genome architecture and function. Cell. 2020;183(1):28-45.

[5] Strom AR, Emelyanov AV, Mir M, Fyodorov DV, Darzacq X, Karpen GH. Phase separation drives heterochromatin domain formation. Nature. 2017;547(7662):241-245.

[6] Kinchen J, Chen HH, Parikh K, et al. Structural remodeling of the human colonic mesenchyme in inflammatory bowel disease. Cell. 2018;175(2):372-386. e17.

[7] Lee JH, Tammela T, Hofree M, et al. Anatomically and functionally distinct lung mesenchymal populations marked by Lgr5 and Lgr6. Cell. 2017;170(6):1149-1163. e12.

[8] Zepp JA, Zacharias WJ, Frank DB, et al. Distinct mesenchymal lineages and niches promote epithelial self-renewal and Myofibrogenesis in the lung. Cell. 2017;170(6):1134-1148. e10.

[9] Zheng Z, Li YN, Jia S, et al. Lung mesenchymal stromal cells influenced by Th2 cytokines mobilize neutrophils and facilitate metastasis by producing complement C3. Nat Commun. 2021;12(1):6202.

[10] Roulis M, Kaklamanos A, Schernthanner M, et al. Paracrine orchestration of intestinal tumorigenesis by a mesenchymal niche. Nature. 2020;580(7804):524-529.

[11] Shi Y, du L, Lin L, Wang Y. Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets. Nat Rev Drug Discov. 2017;16(1):35-52.

[12] Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018;14(8):493-507.

[13] Han Y, Yang J, Fang J, et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct Target Ther. 2022;7(1):92.

[14] Wang Y, Fang J, Liu B, Shao C, Shi Y. Reciprocal regulation of mesenchymal stem cells and immune responses. Cell Stem Cell. 2022;29(11):1515-1530.

[15] Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008;2(2):141-150.

[16] Ren G, Su J, Zhang L, et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells. 2009;27(8):1954-1962.

[17] Li Y, Ma X, Wu W, Chen Z, Meng G. PML nuclear body biogenesis, carcinogenesis, and targeted therapy. Trends Cancer. 2020;6(10):889-906.

[18] Corpet A, Kleijwegt C, Roubille S, et al. PML nuclear bodies and chromatin dynamics: catch me if you can! Nucleic Acids Res. 2020;48(21):11890-11912.

[19] Pearson M, Carbone R, Sebastiani C, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature. 2000;406(6792):207-210.

[20] Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 2000;14(16):2015-2027.

[21] Vernier M, Bourdeau V, Gaumont-Leclerc MF, et al. Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev. 2011;25(1):41-50.

[22] Martin N, Benhamed M, Nacerddine K, et al. Physical and functional interaction between PML and TBX2 in the establishment of cellular senescence. EMBO J. 2012;31(1):95-109.

[23] Wu HC, Rérolle D, Berthier C, et al. Actinomycin D targets NPM1c-primed mitochondria to restore PML-driven senescence in AML therapy. Cancer Discov. 2021;11(12):3198-3213.

[24] Banani SF, Rice AM, Peeples WB, et al. Compositional control of phase-separated cellular bodies. Cell. 2016;166(3):651-663.

[25] Berchtold D, Battich N, Pelkmans L. A systems-level study reveals regulators of membrane-less organelles in human cells. Mol Cell. 2018;72(6):1035-1049. e5.

[26] Delbarre E, Ivanauskiene K, Küntziger T, Collas P. DAXX-dependent supply of soluble (H3.3-H4) dimers to PML bodies pending deposition into chromatin. Genome Res. 2013;23(3):440-451.

[27] Xu S, Wang S, Xing S, et al. KDM5A suppresses PML-RARalpha target gene expression and APL differentiation through repressing H3K4me2. Blood Adv. 2021;5(17):3241-3253.

[28] Luciani JJ, Depetris D, Usson Y, et al. PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodelling at the G2 phase. J Cell Sci. 2006;119(Pt 12: 2518-2531.

[29] Chelbi-Alix MK, Pelicano L, Quignon F, et al. Induction of the PML protein by interferons in normal and APL cells. Leukemia. 1995;9(12):2027-2033.

[30] Grotzinger T, Jensen K, Will H. The interferon (IFN)-stimulated gene Sp100 promoter contains an IFN-gamma activation site and an imperfect IFN-stimulated response element which mediate type I IFN inducibility. J Biol Chem. 1996;271(41):25253-25260.

[31] Wang G, Cao K, Liu K, et al. Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells. Cell Death Differ. 2018;25(7):1209-1223.

[32] Ding Y, Gong P, Jiang J, et al. Mesenchymal stem/stromal cells primed by inflammatory cytokines alleviate psoriasis-like inflammation via the TSG-6-neutrophil axis. Cell Death Dis. 2022;13(11):996.

[33] Shang Q, Chu Y, Li Y, et al. Adipose-derived mesenchymal stromal cells promote corneal wound healing by accelerating the clearance of neutrophils in cornea. Cell Death Dis. 2020;11(8):707.

[34] Braumüller H, Wieder T, Brenner E, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature. 2013;494(7437):361-365.

[35] Zhang W, Li J, Suzuki K, et al. Aging stem cells. A Werner syndrome stem cell model unveils heterochromatin alterations as a driver of human aging. Science. 2015;348(6239):1160-1163.

[36] Bedrosian TA, Houtman J, Eguiguren JS, et al. Lamin B1 decline underlies age-related loss of adult hippocampal neurogenesis. EMBO J. 2021;40(3):e105819.

[37] Matias I, Diniz LP, Damico IV, et al. Loss of lamin-B1 and defective nuclear morphology are hallmarks of astrocyte senescence in vitro and in the aging human hippocampus. Aging Cell. 2022;21(1):e13521.

[38] bin Imtiaz MK, Jaeger BN, Bottes S, et al. Declining lamin B1 expression mediates age-dependent decreases of hippocampal stem cell activity. Cell Stem Cell. 2021;28(5):967-977.e8. e8.

[39] Sladitschek-Martens HL, Guarnieri A, Brumana G, et al. YAP/TAZ activity in stromal cells prevents ageing by controlling cGAS-STING. Nature. 2022;607(7920):790-798.

[40] Hu H, Ji Q, Song M, et al. ZKSCAN3 counteracts cellular senescence by stabilizing heterochromatin. Nucleic Acids Res. 2020;48(11):6001-6018.

[41] Deng L, Ren R, Liu Z, et al. Stabilizing heterochromatin by DGCR8 alleviates senescence and osteoarthritis. Nat Commun. 2019;10(1):3329.

[42] Delbarre E, Janicki SM. Modulation of H3.3 chromatin assembly by PML: a way to regulate epigenetic inheritance. Bioessays. 2021;43(10):e2100038.

[43] Salsman J, Rapkin LM, Margam NN, Duncan R, Bazett-Jones DP, Dellaire G. Myogenic differentiation triggers PML nuclear body loss and DAXX relocalization to chromocentres. Cell Death Dis. 2017;8(3):e2724.

[44] Becker JS, Nicetto D, Zaret KS. H3K9me3-Dependent Heterochromatin: Barrier to Cell Fate Changes. Trends Genet. 2016;32(1):29-41.

[45] McCarthy RL, Zhang J, Zaret KS. Diverse heterochromatin states restricting cell identity and reprogramming. Trends Biochem Sci. 2023;48:513-526.

[46] Absher DM, Li X, Waite LL, et al. Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations. PLoS Genet. 2013;9(8):e1003678.

[47] Leonova K, Safina A, Nesher E, et al. TRAIN (Transcription of repeats activates INterferon) in response to chromatin destabilization induced by small molecules in mammalian cells. Elife. 2018;7:7.

[48] Ding W, Pu W, Wang L, et al. Genome-wide DNA methylation analysis in systemic sclerosis reveals hypomethylation of IFN-associated genes in CD4(+) and CD8(+) T cells. J Invest Dermatol. 2018;138(5):1069-1077.

[49] Sheng W, LaFleur MW, Nguyen TH, et al. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell. 2018;174(3):549-563. e19.

[50] Wang Y, Xie H, Chang X, et al. Single-cell dissection of the multiomic landscape of high-grade serous ovarian cancer. Cancer Res. 2022;82(21):3903-3916.

[51] Beck MA, Fischer H, Grabner LM, et al. DNA hypomethylation leads to cGAS-induced autoinflammation in the epidermis. EMBO J. 2021;40(22):e108234.

[52] Rajshekar S, Yao J, Arnold PK, et al. Pericentromeric hypomethylation elicits an interferon response in an animal model of ICF syndrome. Elife. 2018;7:7.

[53] Delbarre E, Ivanauskiene K, Spirkoski J, et al. PML protein organizes heterochromatin domains where it regulates histone H3.3 deposition by ATRX/DAXX. Genome Res. 2017;27(6):913-921.

[54] Shastrula PK, Sierra I, Deng Z, et al. PML is recruited to heterochromatin during S phase and represses DAXX-mediated histone H3.3 chromatin assembly. J Cell Sci. 2019;132(6):jcs220970.

RIGHTS & PERMISSIONS

2023 2023 The Authors. Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.